At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
Bermekimab Monoclonal Antibody 200 mg +1 moredrug
Likely dose
Bermekimab Monoclonal Antibody 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Bermekimab Monoclonal Antibody 200 mg and Bermekimab Monoclonal Antibody 400 mg for Atopic Dermatitis. Completed, enrolled 38 participants across 1 site.
Detailed Summary
A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionDec 2018
Study CompletionDec 2018
TodayJul 2026
First PostedApr 12, 2018
Enrollment StartMay 21, 2018
Primary CompletionDec 4, 2018
Study CompletionDec 11, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.2 years ago
Interventions
Bermekimab Monoclonal Antibody 200 mgdrug
200 mg subcutaneous injection
Bermekimab Monoclonal Antibody 400 mgdrug
400 mg subcutaneous injection